Short answer · Medically reviewed summary · Last updated: 2026-04-06
Hereditary Angioedema was first formally described by Sir William Osler in 1888, though historical accounts of the condition—then often termed "hereditary angioneurotic edema"—date back to the late 19th century. A History of Discovery While cases were noted by earlier physicians, it was Sir William Osler who solidified the clinical understanding of Hereditary Angioedema by documenting the familial nature of the condition and its distinct, recurring swellings. For decades, the disease was misunderstood as a simple allergic reaction, leading to ineffective treatments like antihistamines and epinephrine, which do not address the underlying biochemical mechanism of Hereditary Angioedema. Evolution of Understanding and Treatment A major turning point occurred in 1963 when researchers Donaldson and Evans identified that patients with Hereditary Angioedema had a deficiency in the C1 esterase inhibitor (C1-INH) protein.
2 people with Hereditary Angioedema have shared their first-person experience on this question at DiseaseMaps.
What is the history of Hereditary Angioedema?
History of Hereditary Angioedema: when and how it was discovered, and the milestones in research since, medically reviewed.
Hereditary Angioedema was first formally described by Sir William Osler in 1888, though historical accounts of the condition—then often termed "hereditary angioneurotic edema"—date back to the late 19th century.
A History of Discovery
While cases were noted by earlier physicians, it was Sir William Osler who solidified the clinical understanding of Hereditary Angioedema by documenting the familial nature of the condition and its distinct, recurring swellings. For decades, the disease was misunderstood as a simple allergic reaction, leading to ineffective treatments like antihistamines and epinephrine, which do not address the underlying biochemical mechanism of Hereditary Angioedema.
Evolution of Understanding and Treatment
A major turning point occurred in 1963 when researchers Donaldson and Evans identified that patients with Hereditary Angioedema had a deficiency in the C1 esterase inhibitor (C1-INH) protein. This discovery transformed the field from an allergy-focused approach to a hematological and immunological one. This shift allowed for the development of targeted therapies. Historically, patients relied on attenuated androgens to increase C1-INH levels, which carried significant side effects. The landscape changed dramatically in the 21st century with the advent of plasma-derived and recombinant C1-INH concentrates like Cinryze and Berinert, followed by innovative kallikrein inhibitors and bradykinin receptor antagonists, which directly target the pathways causing the swellings.
Advocacy and Modern Genetics
The evolution of patient advocacy has been instrumental in raising awareness for Hereditary Angioedema. Organizations such as the U.S. Hereditary Angioedema Association (HAEA) have empowered patients to move beyond the isolation caused by historical misconceptions. Today, advanced genetic testing allows for precise diagnosis by identifying mutations in the SERPING1 gene, moving us away from empirical observation toward personalized, genomic-informed care. As our understanding of Hereditary Angioedema continues to deepen, the focus has shifted from reactive crisis management to proactive, long-term prophylaxis, significantly improving the quality of life for the global community.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Online Mendelian Inheritance in Man (OMIM)
- Orphanet: The portal for rare diseases and orphan drugs
- U.S. Hereditary Angioedema Association (HAEA)
Posted May 23, 2017 by Donna 2250
Posted Nov 29, 2017 by [email protected] 2300
